Daniel Hochstrasser nominated as a new member of Novartis Board of Directors

Bär & Karrer partner Daniel Hochstrasser (pictured) has been nominated for election to the Board of Directors of Novartis, a global healthcare company based in Switzerland, which will take place at the Annual General Meeting on March 4, 2022.  

Daniel Hochstrasser will leave the Bär & Karrer partnership at the end of 2022 after 29 years in the law firm, 10 of which as a senior partner. 

Daniel Hochstrasser is currently serving as co-head of arbitration at Bär & Karrer. In his practice, he focuses on conducting arbitration and litigation, in particular in connection with disputes arising from m&a transactions, industrial and infrastructure projects, banking and finance as well as license, distribution and development agreements, especially in the pharmaceutical sector.